Skip to main content
. Author manuscript; available in PMC: 2013 Apr 1.
Published in final edited form as: J Immunol. 2012 Mar 5;188(7):3513–3521. doi: 10.4049/jimmunol.1102693

FIGURE 2.

FIGURE 2

Erlotinib treatment ameliorates CIA. Following the development of arthritis, DBA1/J mice with CIA were randomly enrolled in a treatment group when they reached a mean arthritic score between 2 and 4. Mice were administered vehicle (n = 10), 10 mg/kg (n = 12), 50 mg/kg (n = 12) erlotinib suspended in vehicle twice daily by oral gavage. A, Arthritis severity was assessed using a visual arthritis scoring system and (B) caliper measurements of paw thickness (*P < 0.05; **P < 0.01). Data represent one experiment of at least three independent experiments. To analyze disease pathology, (C) representative pictures of paw sections were taken, and (D) blinded histological scores of synovitis, pannus formation and bone and cartilage erosion were made (*P < 0.05; **P < 0.01). Bars represent 300 μm. Groups were compared at each time point using a Mann Whitney analysis comparing erlotinib treated mice to vehicle-treated mice. Error bars indicate ± SEM.